← All trials
NCT04922853
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2021
- Primary completion
- Dec 1, 2024
- Completion date
- Dec 1, 2026
- First posted
- Jun 11, 2021
- Last posted
- Jul 27, 2021
- Enrollment
- 562
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sichuan UniversityLead sponsor
- Sichuan UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Sichuan UniversityCollaborator
- Chengdu Fifth People's HospitalCollaborator
- Kunming Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.